Instrument Inactif

Communiqués ProNAi Therapeutics Inc Nasdaq

Actions

US74346L1017

Recherche biotechnologique et médicale

Communiqués

01/07/22	SIERRA ONCOLOGY, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
29/06/22	SIERRA ONCOLOGY, INC. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	AQ
22/06/22	SIERRA ONCOLOGY, INC. : Other Events (form 8-K)	AQ
17/06/22	Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration	BU
01/06/22	SIERRA ONCOLOGY, INC. : Other Events (form 8-K)	AQ
26/05/22	Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting	BU
12/05/22	Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting	BU
06/05/22	Sierra Oncology, Inc: Q1 Earnings Snapshot	AQ
06/05/22	SIERRA ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
06/05/22	Sierra Oncology Reports First Quarter 2022 Results	BU
05/05/22	Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	BU
05/05/22	SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA	BU
02/05/22	SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA	BU
26/04/22	SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA	BU
13/04/22	Sierra Oncology : GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn - Form 8-K	PU
13/04/22	SIERRA ONCOLOGY, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/04/22	GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn	BU
07/04/22	Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	BU
23/03/22	SIERRA ONCOLOGY, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
11/03/22	Sierra Oncology to Participate in the Oppenheimer 32nd Annual Healthcare Conference	BU
10/03/22	Sierra Oncology : Reports 2021 Year End Results - Form 8-K	PU
10/03/22	Sierra Oncology, Inc: Q4 Earnings Snapshot	AQ
10/03/22	SIERRA ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
10/03/22	Sierra Oncology Reports 2021 Year End Results	BU
07/03/22	SIERRA ONCOLOGY, INC. : Change in Directors or Principal Officers (form 8-K)	AQ